- $9.38m
- $10.27m
- 10
- 18
- 53
- 16
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 0.79 | ||
| PEG Ratio (f) | 0.01 | ||
| EPS Growth (f) | 338.75% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 19.42 | 38.85 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +137.5 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.
Directors
- David Platt CHM (67)
- Ola Soderquist CFO (59)
- Mike Sheikh VPR (51)
- Hana Chen-walden IND
- Dale Conaway IND (67)
- Alan Hoberman IND (67)
- Anders Utter IND (53)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- June 9th, 2008
- Public Since
- January 5th, 2010
- No. of Shareholders
- 2,146
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 88,881,858
- Address
- 75 2Nd Ave, Suite 605 Ste 605, NEEDHAM, 02494
- Web
- https://www.bioxytraninc.com/
- Phone
- +1 6174941199
- Auditors
- Fruci & Associates II, PLLC
Upcoming Events for BIXT
Similar to BIXT
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
As of Today at 19:37 UTC, shares in Bioxytran are trading at $0.11. This share price information is delayed by 15 minutes.
Shares in Bioxytran last closed at $0.11 and the price had moved by +12.26% over the past 365 days. In terms of relative price strength the Bioxytran share price has underperformed the S&P500 Index by -0.88% over the past year.
There is no consensus recommendation for this security.
Find out moreBioxytran does not currently pay a dividend.
Bioxytran does not currently pay a dividend.
Bioxytran does not currently pay a dividend.
To buy shares in Bioxytran you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.11, shares in Bioxytran had a market capitalisation of $9.38m.
Here are the trading details for Bioxytran:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BIXT
Based on an overall assessment of its quality, value and momentum Bioxytran is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Bioxytran is $2.71. That is 2468.23% above the last closing price of $0.11.
Analysts covering Bioxytran currently have a consensus Earnings Per Share (EPS) forecast of $0.08 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bioxytran. Over the past six months, its share price has outperformed the S&P500 Index by +5.59%.
As of the last closing price of $0.11, shares in Bioxytran were trading -6.32% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bioxytran PE ratio based on its reported earnings over the past 12 months is 0.79. The shares last closed at $0.11.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bioxytran's management team is headed by:
- David Platt - CHM
- Ola Soderquist - CFO
- Mike Sheikh - VPR
- Hana Chen-walden - IND
- Dale Conaway - IND
- Alan Hoberman - IND
- Anders Utter - IND